Defining Desirable Central Nervous System Drug Space through the Alignment of Molecular Properties, in Vitro ADME, and Safety Attributes
Top Cited Papers
- 25 March 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 1 (6) , 420-434
- https://doi.org/10.1021/cn100007x
Abstract
As part of our effort to increase survival of drug candidates and to move our medicinal chemistry design to higher probability space for success in the Neuroscience therapeutic area, we embarked on a detailed study of the property space for a collection of central nervous system (CNS) molecules. We carried out a thorough analysis of properties for 119 marketed CNS drugs and a set of 108 Pfizer CNS candidates. In particular, we focused on understanding the relationships between physicochemical properties, in vitro ADME (absorption, distribution, metabolism, and elimination) attributes, primary pharmacology binding efficiencies, and in vitro safety data for these two sets of compounds. This scholarship provides guidance for the design of CNS molecules in a property space with increased probability of success and may lead to the identification of druglike candidates with favorable safety profiles that can successfully test hypotheses in the clinic.Keywords
This publication has 33 references indexed in Scilit:
- Defining optimum lipophilicity and molecular weight ranges for drug candidates—Molecular weight dependent lower logD limits based on permeabilityBioorganic & Medicinal Chemistry Letters, 2009
- In Silico Modeling of Nonspecific Binding to Human Liver MicrosomesDrug Metabolism and Disposition, 2008
- Physiochemical drug properties associated with in vivo toxicological outcomesBioorganic & Medicinal Chemistry Letters, 2008
- Understanding mechanisms of toxicity: Insights from drug discovery researchToxicology and Applied Pharmacology, 2008
- In Vitro P-glycoprotein Assays to Predict the in Vivo Interactions of P-glycoprotein with Drugs in the Central Nervous SystemDrug Metabolism and Disposition, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Structure−Brain Exposure RelationshipsJournal of Medicinal Chemistry, 2006
- Research perspectives for pre-screening alternatives to animal experimentationOn the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large sets of chemicalsToxicology and Applied Pharmacology, 2005
- Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: A case study with structurally related piperazinesExperimental and Toxicologic Pathology, 2004
- Can the pharmaceutical industry reduce attrition rates?Nature Reviews Drug Discovery, 2004